Publicacións en colaboración con investigadores/as de Centro Nacional de Investigaciones Cardiovasculares Carlos III (18)

2023

  1. Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction

    Journal of Clinical Medicine, Vol. 12, Núm. 8

  2. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

2022

  1. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  2. Environmental factors like air pollution: not to be forgotten in the 2021 ESC guidelines on heart failure. Response

    Revista Espanola de Cardiologia

  3. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412

  4. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058

  5. The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study

    International Journal of Cardiology, Vol. 361, pp. 116-123

2021

  1. Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI)

    Basic Research in Cardiology, Vol. 116, Núm. 1

2019

  1. Progerin accelerates atherosclerosis by inducing endoplasmic reticulum stress in vascular smooth muscle cells

    EMBO Molecular Medicine, Vol. 11, Núm. 4

2018

  1. Matrix metalloproteinase-10 deficiency delays atherosclerosis progression and plaque calcification

    Atherosclerosis, Vol. 278, pp. 124-134

  2. Vascular smooth muscle–specific progerin expression accelerates atherosclerosis and death in a mouse model of Hutchinson-Gilford progeria syndrome

    Circulation, Vol. 138, Núm. 3, pp. 266-282

2017

  1. Novel phosphate-activated macrophages prevent ectopic calcification by increasing extracellular ATP and pyrophosphate

    PLoS ONE, Vol. 12, Núm. 3

2016

  1. Alternatively activated macrophages exhibit an anticalcifying activity dependent on extracellular ATP/pyrophosphate metabolism

    American Journal of Physiology - Cell Physiology, Vol. 310, Núm. 10, pp. C788-C799

2015

  1. On vascular calcification and plasma levels of pyrophosphate

    Kidney International

  2. Vascular calcification revisited: A new perspective for phosphate transport

    Current Cardiology Reviews, Vol. 11, Núm. 4, pp. 341-351

2013

  1. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment

    Circulation, Vol. 127, Núm. 24, pp. 2442-2451

  2. Determinants of cardiovascular mortality in a cohort of primary care patients with chronic ischemic heart disease. BARBANZA Ischemic Heart Disease (BARIHD) study

    International Journal of Cardiology, Vol. 167, Núm. 2, pp. 442-450

2012

  1. On the role of the type III phosphate transporters in vascular calcification

    Bone